These findings provide corroborating evidence for the hypothesis that targeted therapies against the SAM-dependent methyltransferases of the MLL protein may be a viable therapeutic approach for acute leukemia with the MLL fusion gene or MLL leukemia (Chern et al. 2020). The gene discussed is KMT2A; the disease is leukemia.